✦ LIBER ✦

Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer

✍ Scribed by Mrózek, Ewa; Layman, Rachel; Ramaswamy, Bhuvaneswari; Lustberg, Maryam; Vecchione, Andrea; Knopp, Michael V.; Shapiro, Charles L.

Book ID: 121790468
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 292 KB
Volume: 14
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2014.02.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Neoadjuvant Weekly nab

Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer

✍ Denise A. Yardley; Eric Raefsky; Raul Castillo; Anup Lahiry; Richard LoCicero; D 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 370 KB

Safety data from a phase II study of neo

Safety data from a phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer

✍ D. Yardlev; E. Raefsky; R. Castillo; A. Lahiry; D. Thompson; S. Hanson; C. Meng; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Two Concurrent Phase II Trials of Paclit

Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252

✍ Edith A. Perez; Vera J. Suman; Kendrith M. Rowland; James N. Ingle; Muhammad Sal 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 894 KB

Multicenter Phase II Trial of Neoadjuvan

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

✍ Glück, S. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Paclitaxel and bevacizumab as first-line

Paclitaxel and bevacizumab as first-line treatment in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results a multicenter phase II trial from Hellenic Oncology Research Group

✍ Vamvakas, L.; Karampeazis⁎, A.; Nikolaou, Ch.; Ardavanis, A.; Saloustros, E.; Ka 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 71 KB

Impact of the Addition of Carboplatin an

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

✍ Sikov, William M. (author);Berry, Donald A. (author);Perou, Charles M. (author); 📂 Article 📅 2015 🏛 American Society of Clinical Oncology 🌐 English ⚖ 288 KB